Heartflow (NASDAQ:HTFL) CEO Sells $626,095.50 in Stock

Heartflow, Inc. (NASDAQ:HTFL) CEO John C.M. Farquhar sold 22,562 shares of the stock in a transaction on Friday, July 10th. The stock was sold at an average price of $27.75, for a total value of $626,095.50. Following the completion of the sale, the chief executive officer directly owned 435,373 shares in the company, valued at $12,081,600.75. This represents a 4.93% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

John C.M. Farquhar also recently made the following trade(s):

• On Wednesday, June 24th, John C.M. Farquhar sold 38,900 shares of Heartflow stock. The shares were sold at an average price of $35.00, for a total transaction of $1,361,500.00.
• On Wednesday, June 10th, John C.M. Farquhar sold 22,562 shares of Heartflow stock. The stock was sold at an average price of $28.50, for a total transaction of $643,017.00.
• On Monday, May 11th, John C.M. Farquhar sold 22,562 shares of Heartflow stock. The shares were sold at an average price of $29.12, for a total transaction of $657,005.44.

Heartflow Stock Up 6.9%

Shares of NASDAQ:HTFL opened at $27.25 on Thursday. The company’s 50-day moving average price is $29.97 and its 200 day moving average price is $28.56. The company has a market cap of $2.35 billion and a PE ratio of -8.76. Heartflow, Inc. has a fifty-two week low of $20.13 and a fifty-two week high of $41.22.

Heartflow (NASDAQ:HTFL) last announced its quarterly earnings results on Thursday, May 14th. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.24) by $0.08. The firm had revenue of $52.59 million during the quarter. The company’s revenue for the quarter was up 41.3% on a year-over-year basis. As a group, equities analysts anticipate that Heartflow, Inc. will post -0.82 EPS for the current year.

Analyst Ratings Changes

Several analysts have weighed in on HTFL shares. JPMorgan Chase & Co. cut their target price on Heartflow from $40.00 to $35.00 and set an “overweight” rating on the stock in a research note on Thursday, March 19th. Stifel Nicolaus set a $40.00 price target on Heartflow in a report on Wednesday. Piper Sandler restated an “overweight” rating on shares of Heartflow in a research note on Thursday, June 11th. William Blair began coverage on shares of Heartflow in a report on Monday, May 4th. They issued an “outperform” rating for the company. Finally, Freedom Capital raised shares of Heartflow to a “strong-buy” rating in a research note on Tuesday, June 30th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $37.00.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. TrueMark Investments LLC boosted its position in shares of Heartflow by 1.4% during the 1st quarter. TrueMark Investments LLC now owns 26,885 shares of the company’s stock valued at $654,000 after purchasing an additional 379 shares in the last quarter. Caitong International Asset Management Co. Ltd bought a new stake in shares of Heartflow in the 4th quarter worth approximately $27,000. Strs Ohio raised its holdings in shares of Heartflow by 35.3% in the 1st quarter. Strs Ohio now owns 4,600 shares of the company’s stock worth $112,000 after purchasing an additional 1,200 shares in the last quarter. Russell Investments Group Ltd. acquired a new stake in Heartflow during the fourth quarter valued at approximately $45,000. Finally, Legal & General Group Plc bought a new stake in Heartflow during the third quarter worth approximately $59,000.

Heartflow Company Profile

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.